Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter priori urease in adult volunteers

Infection and Immunity

Volumn 68, Issue 4, 2000, Pages 2135-2141

  Angelakopoulos, Haroula ^a   Hohmann, Elizabeth L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UREASE;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL COLONIZATION; ENZYME ASSAY; EXPRESSION VECTOR; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SALMONELLA ENTERICA; SEROCONVERSION; VACCINATION;

ADMINISTRATION, ORAL; ADULT; ANIMALS; BACTERIAL PROTEINS; BACTERIAL VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HELICOBACTER PYLORI; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MICE; MUCOUS MEMBRANE; MUTATION; PILOT PROJECTS; PLASMIDS; SALMONELLA TYPHIMURIUM; TEMPERATURE; TIME FACTORS; UREASE;

EID: 0034116071     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.68.4.2135-2141.2000     Document Type: Article

References (30)

1. Buchwald, D., and M. Blaser. 1984. A review of human salmonellosis. It Duration of excretion following infection with nontyphi Salmonella. Rev. Infect. Dis. 6:345-346.
2. Carlstedt, G., P. Dahl, P. M. Niklasson, K. Gullberg, G. Banck, and G. Kahlmeter. 1990. Norfloxacin treatment of salmonellosis does not shorten the carrier state. Scand. J. Infect. Dis. 22:553-556.
3. Corthesy-Theulaz, I., S. Hopkins, D. Bachmann, F. Saldinger, N. Porta, R. Haas, Y. Zheng-Xin, T. Meyer, H. Bousourene, A. L. Blum, and J. P. Kraehenbuhl. 1998. Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium expressing urease A and B subunits. Infect. Immun. 66:581-586.
4. DiPetrillo, M. D., T. Tibbetts, H. Kleanthous, K. P. Killeen, and E. L. Hohmann. 1919. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 18:449-459.
5. Forrest, B. D. 1988. Identification of an intestinal immune response using peripheral blood lymphocytes. Lancet i:81-83.
6. Forrest, B. D. 1992. Indirect measurement of intestinal immune responses to an oraly administered attenuated bacterial vaccine. Infect. Immun. 163:336-345.
7. Galan, J. E. 1999. Interaction of Salmonella with host cells through the centisome 63 type III secretion system. Curr. Opin. Microbiol. 2:46-50.
8. Galan, J. E., O. G. Gomez-Duarte, G. A. Losonsky, J. L. Halpern, C. S. Lauderbaugh, S. Kaintuck, M. K. Reymann, and M. M. Levine. 1997. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine 15:700-708.
9. Gilman, R. H., M. Terminel, M. M. Levine, P. Hernandez-Mendoza, and R. B. Hornick. 1975. Relative efficacy of blood, urine, rectal swab, bone-marrow and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet i:1211-1213.
10. Gomez-Duarte, O. G., B. Lucas, Z. X. Yan, K. Panthel, R. Haas, and T. F. Meyer. 1998. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine 16:460-471.
11. Gonzales, C., D. Hone, F. R. Noriega, C. O. Tacket, J. R. Davies, G. Losonsky, P. Nataro, S. Hoffman, A. Malik, E. Nardin, M. B. Sztein, D. G. Heppner, T. R. Fouts, A. Isibasi, and M. M. Levine. 1994. Salmonella typhi vaccine strain CVD908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. 169:927-931.
12. Hohmann, E. L., C. A. Oletta, K. P. Killeen, and S. I. Miller. 1996. phoP/ phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173:1408-1414.
13. Hohmann, E. L., C. A. Oletta, and S. I. Miller. 1995. Evaluation of a phoP/phoQ-deleted aroA deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 14:19-24.
14. Hone, D. M., S. R. Attridge, B. Forrest, R. Morona, D. Daniels, J. T. Labrooy, R. Chiron, A. Bartholomeusz, and D. J. C. Shearson. 1988. A galE Vi-antigen-negative mutant of Salmonella typhi Ty2 retains virulence in humans. Infect. Immun. 56:1326-1333.
15. Hornick, R. B., S. E. Greisman, T. E. Woodward, H. L. DuPont, A. T. Dawkins, and M. J. Snyder. 1970. Typhoid fever: pathogenesis and immunologic control. N. Engl. J. Med. 283:686-691.
16. Ibrahim, G. I., G. H. Fleet, M. J. Lyons, and R. J. Walker. 1985. Method for isolation of highly purified Salmonella flagellins. J. Clin. Microbiol. 22:1040-1044.
17. Kantele, A., H. Arvilommi, and I. Jokinen. 1986. Specific immunoglobulin secreting human blood cells after peroral vaccination against S. typhi. J. Infect. Dis. 153:1126-1131.
18. Lee, C. K., R. Weltzin, W. D. Thomas, Jr., H. Kleenthous, T. H. Ermak, G. Soman, J. E. Hill, S. K. Ackerman, and T. P. Monath. 1995. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J. Infect. Dis. 172:161-172.
19. Lee, V. T., and O. Schneewind. 1999. Type III secretion machines and the pathogenesis of enteric infection caused by Yersinia and Salmonella spp. Immunol. Rev. 168:241-253.
20. Levine, M. M., J. Kaper, D. Herrington, J. Ketley, G. Losonsky, C. O. Tacket, B. Tall, adn S. Cryz. 1988. Safety, immunogenicity and efficacy of recombinant live oral cholera vaccine, CVD103 and CVD103-HgR. Lancet ii:467-70.
21. Miller, S., A. M. Kukral, and J. J. Mekalanos. 1989. A two component regulatory system phoP phoQ controls Salmonella typhimurium virulence. Proc. Natl. Acad. Sci. USA 86:5054-5058.
22. Nakayama, K., S. Kelly, and R. Curtiss III. 1988. Construction of an Asd+ expression-cloning vector: stable maintenance and high level expression of cloned genes in a Salmonella vaccine strain. Bio/Technology 6:693-697.
23. Nardelli-Haefliger, D., J. P. Kraehenbuhl, R. Curtiss III, F. Schodel, A. Potts, S. Kelly, and P. DeGrandi. 1996. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect. Immun. 64:5219-5224.
24. Neill, M. A., S. M. Opan, J. Heelan, R. Giusti, J. E. Cassidy, R. White, and K. H. Mayer. 1991. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann. Intern. Med. 114:195-199.
25. Nelson, J. D., H. Kusmiesz, L. H. Jackson, et al. 1980. Treatment of Salmonella gastroenteritis with ampicillin, amoxicillin or placebo. Pediatrics 65: 1125-1130.
26. Nickerson, C. A., and R. Curtiss III. 1997. Role of sigma factor RpoS in initial stages of Salmonella typhimurium infection. Infect. Immun. 65:1814-1823.
27. Robbe-Saule, V., C. Coynault, and F. Norel. 1995. The live oral typhoid vaccine Ty21a is an rpoS mutant and is susceptible to various environmental stresses. FEMS Microbiol. Lett. 126:171-176.
28. Tacket, C., M. B. Sztein, G. A. Losonsky, S. S. Wasserman, J. P. Nataro, R. Edelman, D. Pickard, G. Dougan, S. N. Chatfield, and M. M. Levine. 1997. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune responses in humans. Infect. Immun. 65:452-456.
29. Tacket, C. O., D. M. Hone, R. Curtiss III, S. M. Kelly, G. Losonsky, L. Guers, A. M. Harris, R. Edelman, and M. M. Levine. 1992. Comparison of the safety and immunogenicity of ΔaroC ΔaroD and Δcya Δcrp Salmonella typhi strains in human volunteers. Infect. Immun. 60:536-541.
30. Tacket, C. O., S. M. Kelly, F. Schodel, G. Losonsky, J. P. Nataro, R. Edelman, M. M. Levine, and R. Curtiss III. 1997. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid encoded hepatitis B antigens stabilized by the asd-balanced lethal vector system. Infect. Immun. 65:3381-3385.